Vitamin D efficacy on COPD
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD).Other chronic obstructive pulmonary disease
- Registration Number
- IRCT2017021030705N1
- Lead Sponsor
- orth Khorasan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 84
Patients with vitamin level more than 20 nano gram per milli liter; age more than 40;patients with diagnosis of severe and very severe COPD; patients who complete the consent form Exclusion criteria: Patient who receive vitamin D supplementation more than 400 unit per day; taking daily dose of systemic corticosteroid(oral or ingection) as maintenance; personal history of one of the following diseases: Osteoporosis, Asthma, renal failure, liver failure, Nephrolithiasis, Hypercalcemia, active TB, Malignancy, Sarcoidosis, Malabsorption; pregnancy and lactation or individuals who want to be pregnant during the study; using of antileptic drugs(barbitorat and phenytoin,) and alcohol; patient with psychological problem; unreliable patients in study.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of quality of life. Timepoint: At time of inclusion, 1, 3, and 6 months after treatment. Method of measurement: m-MRC Questionnaire.;The time of first acute exacerbation. Timepoint: During the study. Method of measurement: Recording in the patients’ information form.;Evaluation of quality of life. Timepoint: At time of inclusion, 1, 3, and 6 months after treatment. Method of measurement: SGQR-C Questionnaire.;Evaluation of quality of life. Timepoint: At time of inclusion, 1, 3, and 6 months after treatment. Method of measurement: CAT Questionnaire.
- Secondary Outcome Measures
Name Time Method The number of hospitalization. Timepoint: During the study. Method of measurement: Recording in the patients’ information form.;Length of stay. Timepoint: During the study. Method of measurement: Recording in the patients’ information form.;Serum level of 25-hydroxyvitamin D. Timepoint: At time of inclusion, 1, 3, and 6 months after treatment. Method of measurement: Measurement of serum level.